Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

NCT07679269 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)
Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)

Interventions

DRUG: Alpelisib
DRUG: Fulvestrant
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Letrozole

Sponsor

Novartis Pharmaceuticals